Navigation Links
WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
Date:10/15/2009

SALT LAKE CITY, Oct. 15 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that the Levacor Ventricular Assist Device (VAD) Bridge-to-Transplant (BTT) Study has been approved by the Institutional Review Board (IRB) at INTEGRIS Baptist Medical Center in Oklahoma City. On-site clinical and technical training has been conducted, formally qualifying this center as the first for the Levacor Study.

Dr. Douglas Horstmanshof is the Program Director of the INTEGRIS Baptist Heart Failure Institute and the center's Principal Investigator for the Levacor trial. Dr. James W. Long is the Study's Co-Investigator and the Director of INTEGRIS Advanced Cardiac Care, which is the only ventricular assist device program in Oklahoma. Both clinicians have long been active in transplant and circulatory support therapies, and Dr. Horstmanshof notes that "we are excited to participate in the Levacor Study and to bring the potential benefits of this unique fourth-generation VAD technology to our heart failure patients."

As previously announced, WorldHeart has conditional approval from the FDA for the Levacor BTT Study for ten initial study sites. Mr. J. Alex Martin, WorldHeart President and CEO said that "we are eager to move forward into the clinical setting and are extremely pleased to announce INTEGRIS Baptist's qualification status. We also continue to work closely with other participating hospitals as their IRBs review the Study protocol."

The Levacor VAD is the only bearingless, fully magnetically levitated, implantable centrifugal pump to enter clinical trial. Mr. Jal S. Jassawalla, WorldHeart's Executive Vice President and Chief Technology Officer, commented "our objective is to demonstrate that this newer-generation technology will minimize complications and provide long-lasting, dependable, performance. We look forward to working with leading clinicians to demonstrate Levacor's safety and efficacy."

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs, the potential clinical benefits of the Levacor VAD, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; successful completion of the Levacor VAD Bridge-to-Transplant Study; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009 and June 30, 2009.

www.worldheart.com

SOURCE World Heart Corporation


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
2. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
3. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
4. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
5. Ortho Clinical Diagnostics Receives FDA Approval for First Anti-HIV 1+2 Test for Use on Random Access, Integrated Laboratory Testing System
6. Prime Therapeutics Receives 2010 TIPPS Certification for Adherence to High Transparency Standards
7. VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ
8. Otix Global Receives Nasdaq Bid Price Notice Deficiency
9. CVS/pharmacys Transportation Operations Receives Two National Safety Awards
10. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
11. Stereotaxis Receives Commitment to Increase and Extend Its Credit Facility With Silicon Valley Bank
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... , the world , s ... and AV fistula intervention   OrbusNeich, a ... solutions, has expanded its portfolio to include products to ... balloons are the company,s first entry devices for lower ...
(Date:5/24/2016)... 24, 2016 ... , la première endoprothèse à double thérapie ... l,intervention portant sur les membres inférieurs et ... OrbusNeich, entreprise mondiale spécialisée dans la fourniture ... vie, a élargi son portefeuille pour inclure ...
(Date:5/24/2016)... 2016 Dutch surgeons have launched a ground-breaking ... world and treat patients on a global scale. Medical professionals from ... Asia and the US have already signed up ... networking in a totally secure environment. Education  ... working together with a surgeon at Harvard to treat a bomb ...
Breaking Medicine Technology:
(Date:5/26/2016)... NJ (PRWEB) , ... May 26, 2016 , ... ... recognized as an NJ Top Doc! Along with his wonderful accolades and stellar ... in podiatry. Congratulations, Dr. Batelli! , Dr. Eugene Batelli is a highly ...
(Date:5/26/2016)... ... ... Bunion Bootie , the manufacturer of the newest and best in ... customer demand over the Mother’s Day Weekend promotion. So much so, that they completely ... completely replenished its inventory levels, it hopes to continue its current sales pace, and ...
(Date:5/26/2016)... , ... May 26, 2016 , ... On May 23rd ... Research Water Life Science® and international water advocate, was honored by Ashram, Inc. as ... in ancient Egypt who knelt on the banks of the Nile to fill their ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The introduction ... WHILE ADDING PROTECTION TO YOUR HEAD ™”. , “We are proud to ... On the football front we have Brian Quick, wide receiver for Los Angeles who ...
(Date:5/26/2016)... Columbus, Ohio (PRWEB) , ... May 26, 2016 ... ... thought leader Mike Morrow-Fox . With over 20 years of experience in ... organizations, as well as several years of university teaching, Morrow-Fox will be featured ...
Breaking Medicine News(10 mins):